Immutep Ltd · ASX:IMM
Immutep — Prima BioMed — FY2013 Earnings Presentation
6 slides from Immutep's earnings presentation, Aug 7, 2013
Slide 1: 4th Quarter Results for FY 2013 – Supplemental Information
Exhibit 99.1 4th quarter (period Supplemental ASX:PRR; 1PRIMA ended BIOMED results NASDAQ:PBMD; information 30 June for FY 2013) 2013 to management ISIN:US74154B2034 discussion August 6, 2013
Slide 2: Important Notice
Important presentation announcements The or expectations from plans, forecast 2PRIMA reliability purpose views assumptions expectations BIOMED byNotice expressed Prima aid of andthe made only beliefs BioMed. orinformation. presentation and expectations in and bybeliefs this about Prima theNothing pr
Slide 3: Highlights
Highlights Approximately CAN-003 Continued Announced Japanese Russell 3PRIMA J.BIOMED method Howard, (phase rollout ofplans the A$7.71 4th of 2to ofovarian PhD use launch the Quarter million patent appointed CAN-004 cancer three for received exploratory, CVac trial) as trial a non-executive –abstrac
Slide 4: R&D Update: CAN-003 and CAN-004
R&D CAN-003: –CAN-004 4P RIMA Topline Immune 38 44 975patients cell clinical patients Update BIOMED collection PFS (CANVAS) monitoring upcoming have centers have andcompleted consented initial centers activated data data – controlled OS for in activated their data to 3rd all and participate 63 first
Slide 5: CVac Saxony: Development Bank awards EUR 3.8 million for CVac trials
CVac Saxony Announced Triple Metastatic Resectable Strong Demonstrated Potential Unmet 5P RIMA–negative background medical exploratory Development BIOMED ofcolorectal pancreatic new mucin immuno-reactive breast needs clinical 1& phase cancer cancer Bank rationale: cancer targets: 2 target (Germany)
Slide 6: Financial Results and Net Cash
Financial Net Cash Projected *according 6PRIMA cash received & term BIOMED outflow results loss todeposits International for from for for FYgrants the the FY 2013: at Quarter end quarter: 2013: inFinancial A$ of Q4: A$ quarter: 15.3 ended A$ A$ 15.31 million 2.55 101,000 Reporting 30 A$ million mill